BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Journavx (Suzetrigine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Journavx (Suzetrigine)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07539623-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261222
DTEND;VALUE=DATE:20261223
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07539623)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine-enhanced 
 MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery\nEstima
 ted primary completion: 22 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07539623
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219888-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07219888)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Comparison of Suzetri
 gine and Oxycodone for Postoperative Pain After Primary Total Knee Arthrop
 lasty\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07219888
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355166-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07355166)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine Versus Us
 ual-care Opioids for Postop Pain in Sports\nEstimated primary completion: 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suzetri
 gine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07355166
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696443-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06696443)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of the Long-term Safety and Effectiveness of 
 Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropa
 thy (DPN)\nEstimated primary completion: 25 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06696443
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548385-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07548385)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine for Treat
 ment and Reduction of Intense Discomfort After knEe Replacement PAIN\nEsti
 mated primary completion: 23 February 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07548385
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07928011-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07928011)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: A Pilot Randomized Co
 ntrolled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Follow
 ing Total Knee Arthroplasty\nEstimated primary completion: March 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07928011
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654296-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07654296)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Assessing Suzetrigine
  for Pain Reduction Following Ureteroscopic Surgery\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07654296
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231419-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07231419)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) f
 or Pain Associated With Diabetic Peripheral Neuropathy\nEstimated primary 
 completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07231419
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628908-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06628908)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine for Pai
 n Associated With Diabetic Peripheral Neuropathy\nEstimated primary comple
 tion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 zetrigine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06628908
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672015-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07672015)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Precision Pain Manage
 ment - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine o
 n Postoperative Analgesia Among Surgical Patients at Higher Risk for Persi
 stent Postoperative Opioid Use (POU)\nEstimated primary completion: June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672015
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821931-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07821931)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4\, Acute Pain.\nStudy: Suzetrig
 ine in Tonsillectomy for Opioid-sparing Pain Management\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07821931
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463430-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270627
DTEND;VALUE=DATE:20270628
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07463430)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine for Non-M
 astectomy Breast Surgery\nEstimated primary completion: 27 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07463430
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525219-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07525219)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine Frame Tri
 al Comparing Suzetrigine and Acetaminophen\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suzetrigin
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 525219
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07600697-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07600697)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine for Opioi
 d-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstruc
 tive Surgery\nEstimated primary completion: 1 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07600697
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07839715-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07839715)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine Post DIEP
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07839715
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145346-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07145346)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4\, Acute Pain.\nStudy: Suzetrig
 ine for Acute Pain Control in Patients With Multiple Rib Fractures\nEstima
 ted primary completion: August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07145346
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07795827-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07795827)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4\, Acute Pain.\nStudy: Suzetrig
 ine for Postoperative Pain After Total Ankle Replacement\nEstimated primar
 y completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07795827
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226700-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07226700)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine in Total 
 Hip Arthroplasty\nEstimated primary completion: 1 November 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07226700
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07575230-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07575230)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine vs Norco-
 postoperative Mohs Pain\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07575230
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796152-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07796152)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine vs. Stand
 ard Care Pain Relief Following Outpatient Knee Replacement Surgery\nEstima
 ted primary completion: December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07796152
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07856654-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07856654)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine Following
  Urogynecologic Surgery: Investigation of Postoperative Pain Management\nE
 stimated primary completion: December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07856654
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836010-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07836010)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine Added to 
 Multimodal Analgesia for Women Undergoing Minimally Invasive Hysterectomy\
 nEstimated primary completion: January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07836010
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07534709-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07534709)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine for Opioi
 d-Free Recovery After Cesarean Delivery\nEstimated primary completion: Feb
 ruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suzetrigi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7534709
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905404-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07905404)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine (Journavx
 ) as Multimodal Therapy for Pain Management in Adults Undergoing Surgery f
 or Hip Fracture\nEstimated primary completion: 30 July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07905404
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624526-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07624526)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Role of Suzetrigine a
 s a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total
  Knee Arthroplasty\nEstimated primary completion: August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07624526
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866638-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07866638)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine for Analg
 esiain Arthroscopic Rotator Cuff Repair\nEstimated primary completion: 1 S
 eptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suzetr
 igine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07866638
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07820969-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07820969)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Post-op Analgesia of 
 Nail Unit Procedures\nEstimated primary completion: 1 October 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07820969
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07864896-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07864896)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3.\nStudy: Suzetrigine in TKA\nE
 stimated primary completion: January 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07864896
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843134-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07843134)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4\, Acute Pain.\nStudy: Suzetrig
 ine Versus Standard Analgesia After Skin Cancer Surgery\nEstimated primary
  completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07843134
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829718-8794@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Journavx (Suzetrigine): Phase 4 readout est. (NCT07829718)
DESCRIPTION:Journavx (Suzetrigine)\, phase 4.\nStudy: Suzetrigine (Journavx
 ) for Pain Management After Spine Surgery\nEstimated primary completion: 3
 0 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/suze
 trigine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07829718
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
